Filing Flows › Opus Genetics (IRD) › Q1 2026 › vs Q1 2025
Opus Genetics (IRD) Q1 2026 vs Q1 2025 (year over year)
Opus Genetics's revenue fell $2.2M (-51%) from $4.4M in Q1 2025 to $2.2M in Q1 2026.
Opus Genetics, Q1 2026: revenue $2.2M (-51% year over year), operating margin -665.9%, net loss $65.5M, operating cash flow −$12.7M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.2M | $4.4M | −$2.2M | -51% |
| Net loss | $65.5M | $8.2M | $57.3M | +700% |
| Costs & expenses | $67.7M | $14.3M | $53.4M | +373% |
| Operating costs | $16.5M | $14.3M | $2.2M | +16% |
| Interest & other, net | $51.2M | −$1.7M | $52.9M | — |
| Research & development | $10.6M | $8.0M | $2.6M | +33% |
| General & admin | $5.9M | $6.3M | −$402K | -6% |
| Operating cash sources | $65.5M | $8.2M | $57.3M | +700% |
| Depreciation | $13K | $13K | $0 | 0% |
| Share-based compensation | $1.5M | $913K | $551K | +60% |
| Working capital & other | $51.3M | −$1.7M | $53.1M | — |
| Cash used in operations | $12.7M | $9.0M | $3.7M | +42% |
| Net loss absorbed | $65.5M | $8.2M | $57.3M | +700% |
Questions
How much did Opus Genetics's revenue grow year over year in Q1 2026?
Opus Genetics's revenue fell $2.2M (-51%) from $4.4M in Q1 2025 to $2.2M in Q1 2026.